Clarissa Desjardins, Congruence CEO

New Or­biMed-backed biotech aims to repli­cate Ver­tex's wild­ly suc­cess­ful cys­tic fi­bro­sis pills in oth­er dis­eases

A new biotech aim­ing to tack­le pro­tein mis­fold­ing has land­ed a sub­stan­tial Se­ries A from some blue-chip in­vestors.

Con­gru­ence Ther­a­peu­tics burst on­to the scene Tues­day with a $50 mil­lion round, in­clud­ing funds from Or­biMed. The biotech will use the mon­ey to ad­vance its plat­form and move some of its pro­grams for­ward, CEO Claris­sa Des­jardins told End­points News.

Tues­day’s round was led by Am­pli­tude Ven­tures and Fonds de sol­i­dar­ité FTQ, a pub­lic de­vel­op­ment fund in Que­bec, Cana­da.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.